Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Contraceptives. On their own.

L Kaeser, J D Forrest, A Rosenfield

    International Journal of Technology Assessment in Health Care
    |January 1, 1992
    PubMed
    Summary
    This summary is machine-generated.

    Contraceptive research faces significant U.S. barriers. Designating contraceptives as orphan drugs could incentivize private companies to develop new, safe, and effective options.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Women's health in perspective: framing problems, framing solutions.

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2007
    Same author

    The FIGO manual of human reproduction.

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2004
    Same author

    Reproductive health and human rights.

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2003
    Same author

    Family planning at heart of political debate.

    Contraceptive technology update·2002
    Same author

    What methods should be included in a contraceptive coverage insurance mandate?

    The Guttmacher report on public policy·2002
    Same author

    Help breast-feeding moms choose hormonal methods.

    Contraceptive technology update·2002
    Same journal

    Measuring, Valuing, and Incorporating Patient and Caregiver Productivity Costs in Economic Evaluations: A Scoping Review and Environmental Scan.

    International journal of technology assessment in health care·2026
    Same journal

    ASSESSING COST EFFECTIVENESS IN ONCOLOGY TREATMENT SEQUENCES: A REVIEW OF PATHWAY MODELLING METHODS FOR HEALTH TECHNOLOGY ASSESSMENT.

    International journal of technology assessment in health care·2026
    Same journal

    Practice and challenges of HB-HTA in China: insights from hospital management and clinical perspectives.

    International journal of technology assessment in health care·2026
    Same journal

    Policy Dialogue on Health Technology Assessment in Middle East and North Africa: Reporting from an HTAi initiative.

    International journal of technology assessment in health care·2026
    Same journal

    What is new in the early health technology assessment's new definition?

    International journal of technology assessment in health care·2026
    Same journal

    Incorporating climate impact in health care decisions: new criteria to be tested in the Netherlands.

    International journal of technology assessment in health care·2026
    See all related articles

    Area of Science:

    • Reproductive Health
    • Pharmaceutical Policy
    • Drug Development

    Background:

    • Significant unmet needs exist for safe and effective contraceptive methods.
    • The United States faces substantial obstacles in contraceptive research and development.
    • Private sector involvement in contraceptive innovation has declined.

    Purpose of the Study:

    • To explore strategies for overcoming barriers in contraceptive research and development.
    • To evaluate the potential of orphan drug designation for stimulating contraceptive innovation.

    Main Methods:

    • Policy analysis of existing pharmaceutical incentives.
    • Review of historical trends in contraceptive research funding and development.
    • Assessment of the orphan drug designation framework.

    Related Experiment Videos

    Main Results:

    • Contraceptive development is hindered by regulatory and market challenges.
    • Orphan drug designation offers incentives like market exclusivity and tax credits.
    • These incentives have historically encouraged development in other therapeutic areas.

    Conclusions:

    • Designating contraceptives as orphan drugs is a viable strategy to encourage private sector reentry.
    • Such a policy could foster innovation and address unmet needs in reproductive health.
    • Addressing research and development barriers is crucial for advancing contraceptive options.